Market Overview

UPDATE: Oppenheimer Downgrades Emerson to Perform on Lack of Catalysts to Growth

Share:
Related EMR
Lightning Round: Jim Cramer Gives His Opinion On Delta, Sangamo, Kinder Morgan And More
Benzinga's Top Upgrades, Downgrades For October 17, 2017

Oppenheimer reduced its rating on Emerson (NYSE: EMR) from Outperform to Perform and lowered its price target from $57 to $53.

Oppenheimer commented, "We are downgrading shares of EMR to Perform from Outperform, based on lack of high conviction catalysts to drive multiple expansion, and nearterm risk associated with exposure to capital spending. Initial guidance outlook for msd-hsd EPS growth appears a potentially more opportunistic backdrop for expectations, but does include a combined 17c headwind from pension and overlapping stock compensation plans (partially offset by ~6c favorable from lower restructuring spend, and material restructuring benefits)."

Emerson closed at $48.36 on Monday.

Latest Ratings for EMR

DateFirmActionFromTo
Oct 2017Cowen & Co.UpgradesMarket PerformOutperform
Oct 2017Bank of AmericaUpgradesNeutralBuy
Oct 2017CitigroupMaintainsSell

View More Analyst Ratings for EMR
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (EMR)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...